MX2020010469A - Inhibidores del atf6 y sus usos. - Google Patents

Inhibidores del atf6 y sus usos.

Info

Publication number
MX2020010469A
MX2020010469A MX2020010469A MX2020010469A MX2020010469A MX 2020010469 A MX2020010469 A MX 2020010469A MX 2020010469 A MX2020010469 A MX 2020010469A MX 2020010469 A MX2020010469 A MX 2020010469A MX 2020010469 A MX2020010469 A MX 2020010469A
Authority
MX
Mexico
Prior art keywords
atf6
inhibitors
diseases
compounds
treatment
Prior art date
Application number
MX2020010469A
Other languages
English (en)
Inventor
Sarvajit Chakravarty
Balaji Dashrath Sathe
Sebastian Bernales
Brahmam Pujala
Vasquez Gonzalo Esteban Núñez
Jennifer Alfaro
Sebastian Belmar
Pooja Thakral
Rajesh Kumar Patidar
Original Assignee
Praxis Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biotech LLC filed Critical Praxis Biotech LLC
Publication of MX2020010469A publication Critical patent/MX2020010469A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos como inhibidores del factor de transcripción activador 6 (ATF6). Los compuestos pueden ser útiles como agentes terapéuticos para tratar enfermedades o trastornos mediados por ATF6 y pueden ser particularmente útiles para tratar infecciones virales, enfermedades neurodegenerativas, enfermedades vasculares o cáncer.
MX2020010469A 2018-04-06 2019-04-06 Inhibidores del atf6 y sus usos. MX2020010469A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862654263P 2018-04-06 2018-04-06
PCT/US2019/026198 WO2019195810A2 (en) 2018-04-06 2019-04-06 Atf6 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2020010469A true MX2020010469A (es) 2021-04-19

Family

ID=66248737

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020010469A MX2020010469A (es) 2018-04-06 2019-04-06 Inhibidores del atf6 y sus usos.
MX2023010326A MX2023010326A (es) 2018-04-06 2020-10-02 Inhibidores de atf6 y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023010326A MX2023010326A (es) 2018-04-06 2020-10-02 Inhibidores de atf6 y sus usos.

Country Status (14)

Country Link
US (3) US10829485B2 (es)
EP (1) EP3774782A2 (es)
JP (1) JP7476167B2 (es)
KR (1) KR20210028144A (es)
CN (1) CN112313224A (es)
AU (1) AU2019247533B2 (es)
BR (1) BR112020020181A2 (es)
CA (1) CA3096139A1 (es)
CL (1) CL2020002573A1 (es)
IL (1) IL277794B2 (es)
MX (2) MX2020010469A (es)
RU (1) RU2020136310A (es)
SG (1) SG11202009570SA (es)
WO (1) WO2019195810A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220389001A1 (en) * 2019-10-09 2022-12-08 Praxis Biotech LLC Atf6 modulators and uses thereof
CN115087656A (zh) * 2019-10-09 2022-09-20 普拉西斯生物技术有限责任公司 Atf6调节剂及其用途
EP4001917A1 (en) 2020-11-12 2022-05-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Inhibitors for use in treating liver disorders
KR102644194B1 (ko) * 2021-02-22 2024-03-08 주식회사 이노셀젠헬스케어 종양의 진단 및 치료를 위한 표적단백질로서의 atf6
WO2022266232A1 (en) * 2021-06-16 2022-12-22 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for treating chronic liver disease and hepatocellular carcinoma
CN113501787A (zh) * 2021-08-20 2021-10-15 黑龙江省科学院石油化学研究院 一种合成6-三氟甲基-3-甲基吲唑的方法
WO2024015425A1 (en) 2022-07-14 2024-01-18 Fmc Corporation Herbicidal benzoxazines
KR20240030727A (ko) * 2022-08-31 2024-03-07 단국대학교 천안캠퍼스 산학협력단 퓨릴티아졸계 화합물 및 이를 유효성분으로 포함하는 근감소증 예방 또는 치료용 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1371647E (pt) * 1998-04-20 2005-10-31 Pfizer Derivados do acido piridina-3-carboxilico e sua utilizacao como intermediarios
ES2350837T3 (es) * 2003-05-01 2011-01-27 Bristol-Myers Squibb Company Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas.
WO2007073300A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
AR069650A1 (es) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8901306B2 (en) * 2009-03-02 2014-12-02 Stemsynergy Therapeutics, Inc. Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
ES2842399T3 (es) * 2009-12-22 2021-07-14 Vertex Pharma Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
BR112015002938A2 (pt) * 2012-08-10 2017-08-08 Hoffmann La Roche compostos de carboxamida pirazol, composições e métodos de uso
US20150272959A1 (en) * 2012-10-04 2015-10-01 Oyagen, Inc. Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof
CN107438603B (zh) * 2015-04-22 2021-08-10 里格尔药品股份有限公司 吡唑化合物以及制备和使用该化合物的方法
EP3312170A4 (en) * 2015-06-22 2018-12-12 Sumitomo Dainippon Pharma Co., Ltd. 1,4-di-substituted imidazole derivative
CN114716381A (zh) * 2015-12-16 2022-07-08 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
US10898469B2 (en) * 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
US10357477B2 (en) * 2016-09-13 2019-07-23 Regents Of The University Of Minnesota Anticancer compounds

Also Published As

Publication number Publication date
IL277794B1 (en) 2023-10-01
CN112313224A (zh) 2021-02-02
US20190367497A1 (en) 2019-12-05
CL2020002573A1 (es) 2021-03-05
IL277794A (en) 2020-11-30
RU2020136310A (ru) 2022-05-06
CA3096139A1 (en) 2019-10-10
US20240124434A1 (en) 2024-04-18
JP2021521271A (ja) 2021-08-26
WO2019195810A3 (en) 2019-11-21
KR20210028144A (ko) 2021-03-11
EP3774782A2 (en) 2021-02-17
JP7476167B2 (ja) 2024-04-30
BR112020020181A2 (pt) 2021-01-19
MX2023010326A (es) 2023-09-14
AU2019247533B2 (en) 2023-09-28
SG11202009570SA (en) 2020-10-29
RU2020136310A3 (es) 2022-05-06
IL277794B2 (en) 2024-02-01
AU2019247533A1 (en) 2020-10-15
US10829485B2 (en) 2020-11-10
WO2019195810A2 (en) 2019-10-10
US20210221803A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
MX2023010326A (es) Inhibidores de atf6 y sus usos.
PH12018502429A1 (en) Antibody molecules for cancer treatment
SA518391624B1 (ar) Ror- منظمات جاما
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2023002507A (es) Inhibidores de cd73.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
WO2018026722A8 (en) COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
MD20160138A2 (ro) Combinaţie
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
PH12021550872A1 (en) Therapeutic compounds
JO3789B1 (ar) التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
NZ788133A (en) Cd73 inhibitors
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2021004598A (es) Inhibidores selectivos de rgmc y el uso de los mismos.
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MX2021003152A (es) Piridazinonas y sus metodos de uso.
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.